Sarepta Therapeutics

Head of R&D and Chief Scientific Officer Louise Rodino-Klapac, PhD, on the promise Sarepta sees in today’s global licensing and collaboration agreement with Arrowhead Pharmaceuticals.?

CEO Doug Ingram on Sarepta’s global licensing and collaboration agreement with Arrowhead Pharmaceuticals and how the agreement will help solidify Sarepta’s position as a genetic medicine leader.?

Today we announced a licensing and collaboration agreement with Arrowhead Pharmaceuticals that will provide Sarepta with exclusive global rights to multiple clinical, pre-clinical and discovery stage programs for rare, genetic diseases.?

How might wearables change the future of clinical trials? Ask Landry, a playful 10-year-old from Iowa and a clinical trial pioneer. Landry lives with #Duchenne muscular dystrophy and recently participated in a Sarepta clinical trial that included a wearable device measuring stride speed. Incorporating novel endpoints, such as data from a wearable device, into clinical trials allows Sarepta to see the whole patient and evaluate how therapies may impact a person beyond the clinic appointment and in their everyday life. Visit our Newsroom to read more about Landry’s story and the potential for wearables in Duchenne drug developments: https://bit.ly/40Vi2tA #raredisease #clinicaltrials #wearables?

November 17 is National Employee Resource Group (ERG) Day and a good time to acknowledge the many dedicated Sarepta colleagues who bring our ERGs to life. (Thank you!) ERGs are woven into the fabric of our Sarepta culture, and more than half of our colleagues participate as active members of an ERG. Each Sarepta ERG aims to foster an environment where our colleagues feel valued for their unique perspectives and are empowered to contribute to the success of our organization and their personal career growth. Our ERGs include: ?DisCO – Our Disability Community (DisCO) ERG welcomes people living with physical, cognitive, or intellectual disabilities, nonvisible and undiagnosed diseases, psychiatric or sensory differences, or are allies, advocates or caregivers of these and related communities. ? HUES – Aims to attract, retain and facilitate the development of Black employees by providing opportunities to grow and develop talented, engaged leaders who represent and reinforce the mission and vision of Sarepta. ? M-ERG – Sarepta’s Multicultural Employee Resource Group was created to embrace, promote and celebrate Sarepta’s cultural diversity and to foster a culture of inclusion and appreciation for employees of varied backgrounds. ?Pride – Our ERG for employees who identify as LBGTQ along with their allies provides members with a forum to promote a dynamic, welcoming, and friendly atmosphere while strengthening diversity and inclusion at Sarepta. ?Spark – Fuels employee career growth and development to cultivate future industry leaders through networking and mentoring opportunities and forming meaningful connections within Sarepta and our broader community. ? Sarepta Women’s Alliance – SWA provides a community of support to facilitate the development of women within Sarepta by providing leadership opportunities to grow and develop talented, engaged leaders who represent and reinforce the mission and vision of Sarepta. #ERGDay #OneSarepta #Inclusion

Thank you to Marissa Penrod, founder and CEO of Team Joseph, a Duchenne patient advocacy organization, for joining us for a powerful conversation on caregiving in Duchenne. Marissa and other Duchenne caregivers shared their experiences of caring for and supporting loved ones with Duchenne. They offered insights from Team Joseph’s newly released white paper “Engulfed in Caregiving.” This resulted from a Team Joseph research project and highlights the perspectives, hardships and triumphs of a diverse group of Duchenne caregivers. Sarepta is proud to be one of the supporters of this important work. Caregivers are a critical part of the Duchenne community, and it is vital for us to continually hear and understand their perspectives. The event underscores our patient mission and commitment to the community, and we are grateful for the time and learnings. Thank you!

On our #Q3Results call, Chief Customer Officer Dallan Murray shared details on an impressive third quarter, led by the continued strength of our gene therapy launch.

On our #Q3Results call, CEO Doug Ingram discussed our third-quarter performance and shared an update on recent corporate developments.

We're excited to share our new therapy for Duchenne has been recognized as one of TIME’s Best Inventions of 2024! To learn more about Sarepta and our contributions to the rare disease community, visit: Sarepta.com #TIMEBestInventions

Are you familiar with the North Star Ambulatory Assessment (NSAA)? Sarepta’s Senior Director of Global Medical Affairs, Rachel Salazar, PT, DPT, PhD, offers a clear explanation of the clinical outcome measurement tool designed specifically for people living with #Duchenne. By rating 17 different motor skill activities, doctors can keep an eye on how a child’s functional performance changes over time due to disease progression. As Rachel shares, kids typically reach their peak score and performance around 6 years of age before entering a decline in their functional skills. “If we look at 9-year-old with Duchenne, no change or even a one-point decline is rather unexpected because this child would be typically in the steep decline phase of his disease. And if the North Star holds steady rather than declining each year, then he may be retaining abilities that he was expected to lose due to his disease.” Watch the video to learn more and view Sarepta’s fact sheet outlining the complete list of 17 measured skills. https://bit.ly/3YjVFuG #raredisease